Aphios Pharma (2)

Aphios is developing enabling technology platforms designed to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Using these enabling technology platforms, Aphios and its collaborators are developing enhanced therapeutics for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders.

 

Developing cannabis therapeutics as alternatives to synthetic drugs for highly unmet medical needs
Addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis
$44 million spent to date on developing enabling drug manufacturing and drug delivery technologies
$7.9M peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH
Supercritical fluid facility for manufacturing 1,000 kg pharma-grade cannabinoids per yr under cGMP
Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids
Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued and 4 provisional patents
We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change

Trevor P. Castor, President & CEO
Dr. Castor has developed green enabling platforms for improving drug discovery and manufacturing, and nanotechnology drug delivery in an environmentally sustainable manner and nanoencapsulated cannabinoids for cancer pain, MS and opioid use disorder.

Dr. Val Livada, Busines Advisor
Dr. Val R. Livada is Founder and CEO of Weybridge Partners which is focused on successful technology commercialization. He was a Senior Lecturer (retired) on Corporate Entrepreneurship at the Sloan School of Management, MIT, Cambridge, MA.